BiotechTube

SAR447537 + Zemaira

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alpha 1-Antitrypsin Deficiency

Conditions

Alpha 1-Antitrypsin Deficiency, Emphysema

Trial Timeline

Oct 12, 2023 → Aug 6, 2025

NCT ID
NCT05856331

About SAR447537 + Zemaira

SAR447537 + Zemaira is a phase 2 stage product being developed by Sanofi for Alpha 1-Antitrypsin Deficiency. The current trial status is completed. This product is registered under clinical trial identifier NCT05856331. Target conditions include Alpha 1-Antitrypsin Deficiency, Emphysema.

What happened to similar drugs?

2 of 9 similar drugs in Alpha 1-Antitrypsin Deficiency were approved

Approved (2) Terminated (0) Active (7)
✅CE1226CSLApproved
✅Alpha1-proteinase inhibitorCSLApproved
🔄alpha-1 proteinase inhibitor (human)GrifolsPhase 3
🔄Alpha-1 MP + alpha-1 proteinase inhibitor (human)GrifolsPhase 3
🔄Alpha-1 MPGrifolsPhase 3
🔄Alpha-1 MPGrifolsPhase 3
🔄Placebo Matching Mitapivat + MitapivatAgios PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05856331Phase 2Completed

Competing Products

20 competing products in Alpha 1-Antitrypsin Deficiency

See all competitors
ProductCompanyStageHype Score
Drug-Carbamazepine (Tegretol XR) + Carbamazepine (Tegretol XR) PlaceboNovartisPhase 2
27
BelcesiranNovo NordiskPhase 2
27
belcesiran + PlaceboNovo NordiskPhase 1
29
Belcesiran + Belcesiran + BelcesiranNovo NordiskPhase 2
27
VX-668 + PlaceboVertex PharmaceuticalsPhase 1
29
VX-864 + PlaceboVertex PharmaceuticalsPhase 2
35
VX-634 + PlaceboVertex PharmaceuticalsPhase 1
29
VX-814 + PlaceboVertex PharmaceuticalsPhase 2
27
VX-864Vertex PharmaceuticalsPhase 2
27
SAR447537SanofiPhase 2
42
Alpha-1 Antitrypsin (human)CSLPhase 2
35
CE1226CSLApproved
50
Alpha1-proteinase inhibitorCSLApproved
43
ALN-AAT02 + Placebo + ALN-AAT02Alnylam PharmaceuticalsPhase 1/2
21
BMN 349 + PlaceboBioMarin PharmaceuticalPhase 1
33
ARO-AAT InjectionArrowhead PharmaceuticalsPhase 1
26
ARC-AAT Injection + DiphenhydramineArrowhead PharmaceuticalsPhase 1
18
ARC-AAT InjectionArrowhead PharmaceuticalsPhase 2
24
Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor + Dose of 60 mg/kg alpha1-proteinase inhibitorBaxterPhase 1
26
ARO-AATArrowhead PharmaceuticalsPhase 2
32